AnaCardio selected as finalist at the J.P. Morgan Asset Management: Life Sciences Innovation Summit
Stockholm, Sweden, April 4 , 2024 AnaCardio, a Swedish clinical-stage biopharmaceutical company focused on developing novel contractile agents to treat patients with heart failure, announced today that it has been selected as one of 11 finalists to present at the inaugural J.P. Morgan Asset Management: Life Sciences Innovation Summit. The summit will take place on […]